. Author manuscript; available in PMC: 2015 Jan 1.

Published in final edited form as: Nat Biotechnol. 2014 Jun 22;32(7):644–652. doi: 10.1038/nbt.2940

Table 1.

Overview of TCGA samples and high-throughput characterization platform information by cancer type

Cancer	Overall Survival	SCNA	Methy	mRNA	miRNA	Protein	Core set
GBM		SNP_6	27k	AgilentG4502A	H-miRNA_8x15K	RPPA^*
GBM	565	563	287	492	491	214	210
KIRC		SNP_6	450k	HiseqV2	GA+Hiseq	RPPA
KIRC	500	493	283	469	454	480	243
OV		SNP_6	27k	AgilentG4502A	H-miRNA_8x15K	RPPA
OV	563	559	600	558	586	412	379
LUSC		SNP_6	450k^*	HiseqV2	GA+Hiseq	RPPA
LUSC	305	343	225	220	351	195	121

For each cancer type, the first row shows the platforms and the second row shows the sample counts. SNP_6: Affymetrix Genome-Wide Human SNP Array 6.0; 27k: Illumina Infinium Human DNA Methylation 27K, 450k: Illumina Infinium Human DNA Methylation 450K; AgilentG4502A: Agilent 244K Custom Gene Expression G4502A; HiseqV2: Illumina HiSeq 2000 RNA Sequencing V2; H-miRNA_8x15K: Agilent 8×15K Human miRNA-specific microarray platform; GA+Hiseq: Illumina Genome Analyzer/HiSeq 2000 miRNA sequencing platform; RPPA: MD Anderson Reverse Phase Protein Array.

The data type was not included in that cancer type.